The Fibrin Pad Cardiovascular Study
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Jerome Riebman, MD
Ethicon, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Clinical Investigation Site #5
Indianapolis, Indiana, United States
- Clinical Investigation Site #6
Kansas City, Missouri, United States
- Clinical Investigation Site #4
Camden, New Jersey, United States
- Clinical Investigation Site #1
Paterson, New Jersey, United States
- Clinical Investigation Site #2
New York, New York, United States
- Clinical Investigation Site #3
New York, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Aug 2012
- Primary completion
- 1 Aug 2013
- Completion
- 3 Sept 2013
- Last update posted
- 12 Jun 2018
- Registered enrollment
- 42
- Registry id
- NCT01681030
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.